STOCK TITAN

Axogen (AXGN) Stock News

AXGN NASDAQ

Axogen, Inc. develops and commercializes surgical solutions for peripheral nerve regeneration and repair. The company’s recurring updates center on its portfolio for restoration of peripheral nerve function, including Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.

Company news also includes quarterly and annual financial results, revenue guidance, gross margin and cash metrics, investor-conference participation, FDA-related developments for Avance, and capital-structure actions involving common stock. These updates connect operating performance with Axogen’s commercial activity in nerve repair products across its target markets.

Rhea-AI Summary

Axogen (AXGN) management is scheduled to participate in three upcoming investor conferences, with appearances beginning on November 11, 2026.

Fireside chats are scheduled for the Canaccord Genuity forum on November 11 at 10:00 AM ET and Jefferies conference in London on November 17 at 8:30 AM ET. A Piper Sandler presentation is scheduled for December 2 at 8:00 AM ET. Each event includes one-on-one investor meetings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.70%
Tags
conferences
-
Rhea-AI Summary

Axogen (NASDAQ: AXGN) reported third-quarter revenue of $75.8 million, up from the same quarter last year, and raised its full-year revenue guidance. Revenue grew 26.2% year over year. Net income rose to $2.3 million, or $0.04 per diluted share, from $0.7 million, or $0.01 per diluted share. Gross margin fell to 74.8% from 76.6%.

Axogen expects 2026 revenue of at least $290 million, representing growth of at least 29%, including at least $7 million from BioCircuit. Organic revenue is expected to reach at least $283 million, up at least 26%. Gross-margin guidance remains at least 73%, with positive full-year free cash flow expected. Axogen completed its BioCircuit acquisition on October 1, 2026. An offering raised $225 million net through 5,646,500 common shares; $200 million funded the acquisition and $1.9 million funded transaction expenses. Cash, restricted cash and investments totaled $350.1 million at September 30.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.47%
Tags
-
Rhea-AI Summary

Axogen (AXGN) will release its third-quarter 2026 financial results on October 28, 2026, followed by a management conference call.

The investment-community call and webcast will begin at 8:00 a.m. ET. A live webcast, archived replay and presentation slides will be available on the Investors page at www.axogeninc.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.85%
Tags
earnings date
Rhea-AI Summary

Axogen (AXGN) has completed its previously announced acquisition of BioCircuit Technologies, adding NerveTape to its peripheral nerve repair portfolio.

NerveTape is an FDA-cleared sutureless device for repairing transected, or severed, nerves. BioCircuit is a privately held medical device company that develops and commercializes devices for peripheral nerve repair and neuromodulation.

Axogen expects BioCircuit to contribute approximately $6 million to fourth-quarter 2026 revenue and approximately $34 million to 2027 revenue. This contribution was not included in its most recently issued full-year 2026 guidance of at least 24% revenue growth. The company continues to expect gross margin of at least 73% and to be free cash positive for full-year 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.34%
Tags
-
Rhea-AI Summary

Axogen (AXGN) priced an underwritten public offering of 4,910,000 common shares at $42.50 per share on September 10, 2026.

The company expects gross proceeds of approximately $208.7 million, excluding any exercise of the underwriters’ 30-day option to purchase up to an additional 736,500 shares at the same public price, less underwriting discounts and commissions. The offering is expected to close on September 11, 2026, subject to customary conditions. Axogen plans to use substantially all net proceeds to fund the cash consideration and related fees for its previously announced BioCircuit Technologies acquisition, with any remaining funds, or all proceeds if the deal does not close, for general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.47%
Tags
-
Rhea-AI Summary

Axogen (AXGN) agreed to acquire BioCircuit Technologies for $200 million in cash, adding the FDA-approved sutureless nerve repair device NerveTape™.

The cash consideration at closing is subject to customary adjustments, with $1.0 million withheld pending a post-closing purchase price adjustment. Closing is expected in the fourth quarter of 2026, contingent on standard conditions, including completion of a spin-out of BioCircuit’s electronics research and development business. NerveTape, described as the first FDA-approved device for sutureless peripheral nerve repair, is expected to broaden Axogen’s addressable market and benefit from its existing sales force, surgeon relationships and hospital contracting.

Axogen expects the deal to be accretive to revenue growth, adjusted EBITDA margin and adjusted EPS in the first year after closing while remaining free cash flow positive, and to be additive to 2027 revenue with accretion to 2027 gross and adjusted EBITDA margins.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.47%
Tags
Rhea-AI Summary

Axogen (NASDAQ: AXGN) announced that its management team will participate in the 24th Annual Morgan Stanley Global Healthcare Conference. According to Axogen, management will be available for one-on-one investor meetings at the event on Tuesday, September 15, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
none
-
Rhea-AI Summary

Trace Biosciences, a clinical-stage biotech focused on nerve-targeted imaging agents, announced a strategic investment from Axogen (NASDAQ: AXGN) as part of Trace's Series A financing. Axogen is described as a global leader in surgical solutions for peripheral nerve repair.

The proceeds are earmarked to advance Trace's Nerve Trace near-infrared fluorescence imaging technology, which provides real-time visualization of nerves during surgery. Trace's lead candidate, Nerve Trace Dx, received FDA IND clearance in December 2025 and has begun a Phase I trial evaluating safety and feasibility in surgical patients, with the new capital intended to support planned Phase II and III trials toward a potential NDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
-
Rhea-AI Summary

Axogen (NASDAQ: AXGN) reported Q2 2026 revenue of $69.7 million, up 23.1% from $56.7 million a year earlier, with gross margin of 72.7% versus 74.2%. The quarter showed a GAAP net loss of $1.5 million ($0.03/share) compared with net income of $0.6 million, while adjusted net income was $7.3 million ($0.12/share) versus $5.7 million. Adjusted EBITDA was $8.4 million, down from $9.3 million. Cash, restricted cash, and investments rose to $113.4 million at June 30, 2026, from $103.6 million at March 31, 2026. For 2026, Axogen now expects at least 24% revenue growth, or at least $279 million, gross margin of at least 73%, and positive full-year free cash flow. The company also highlighted broad-based growth across key clinical markets, new Level 1 evidence for Axoguard Nerve Cap, initiation of the Nerve-RESTORE study, and a minority stake in Trace Biosciences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
Rhea-AI Summary

Axogen (Nasdaq: AXGN) announced it will release its second quarter 2026 financial results on Wednesday, July 29, 2026. Management will host a conference call and webcast at 8:00 a.m. ET. Phone access is via (877) 407-0993 or (201) 689-8795, with webcast and replay on the Axogen Investors webpage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
earnings date

FAQ

What is the current stock price of Axogen (AXGN)?

Axogen (AXGN) last closed at $56.95.

What is the market cap of Axogen (AXGN)?

The market cap of Axogen (AXGN) is approximately $3.4B.